Gossamer Bio (NASDAQ:GOSS) Trading Down 4.7% – Time to Sell?

Gossamer Bio, Inc. (NASDAQ:GOSS) shares traded down 4.7% on Wednesday . The company traded as low as $2.57 and last traded at $2.5360. 294,409 shares changed hands during trading, a decline of 93% from the average session volume of 4,517,363 shares. The stock had previously closed at $2.66.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GOSS. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Gossamer Bio currently has an average rating of “Moderate Buy” and an average target price of $8.50.

Gossamer Bio Trading Down 4.7%

The firm has a market cap of $586.75 million, a P/E ratio of -3.67 and a beta of 1.92. The company’s fifty day moving average price is $3.08 and its two-hundred day moving average price is $2.53.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $13.29 million during the quarter, compared to analyst estimates of $6.32 million. Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. On average, analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in Gossamer Bio during the 2nd quarter valued at $26,000. Ciovacco Capital Management LLC bought a new stake in shares of Gossamer Bio during the third quarter worth $27,000. Banco BTG Pactual S.A. acquired a new stake in shares of Gossamer Bio in the second quarter valued at $27,000. Drive Wealth Management LLC increased its stake in shares of Gossamer Bio by 52.7% in the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after buying an additional 8,797 shares in the last quarter. Finally, Brighton Jones LLC bought a new position in shares of Gossamer Bio in the third quarter valued at about $36,000. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.